Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

MVASI

BEVACIZUMAB-AWWB

Standard Dose
400MG/16ML (25MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview MVASI is listed in Drugs@FDA under application 761028 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB-AWWB Form and strength INJECTABLE; INJECTION - 400MG/16ML (25MG/ML) Sponsor AMGEN INC Submission history Latest submission status date: 2023-02-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview MVASI is listed in Drugs@FDA under application 761028 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB-AWWB Form and strength INJECTABLE; INJECTION - 400MG/16ML (25MG/ML) Sponsor AMGEN INC Submission history Latest submission status date: 2023-02-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.